Short-term renal and patient outcomes of primary immunoglobulin-associated mesangiocapillary glomerulonephritis: Insights from a developing country

Table 3 Treatment and renal outcomes in patients with and without the requirement of kidney replacement therapy on presentation over 2 years

Parameters	Overall, n = 163	KRT required on presentation, n = 43	KRT not required on presentation, n = 120	P value
Steroids alone	62 (38.0)	21 (48.83)	41 (34.16)	0.08
CR	9 (5.52)	2 (4.65)	7 (5.83)	0.42
PR	36 (22.08)	3 (6.97)	33 (27.5)	< 0.001
ESKD	12 (7.36)	12 (27.90)	0	< 0.001
Mortality	5 (3.06)	4 (9.30)	1 (0.83)	0.04
Cyclophosphamide + steroids	21 (12.8)	5 (11.62)	16 (13.33)	0.13
CR	4 (2.45)	0	4 (3.33)	0.53
PR	13 (7.97)	1 (2.32)	12 (10)	0.02
ESKD	3 (1.84)	3 (6.97)	0	< 0.001
Mortality	1 (0.61)	1 (2.32)	0	0.06
Renal outcomes at 2 years
CR	56 (34.3)	3 (6.97)	53 (44.1)	< 0.001
PR	68 (41.71)	5 (11.6)	63 (52.5)	< 0.001
ESKD	32 (19.63)	29 (67.41)	3 (2.5)	< 0.001
Mortality	7 (4.29)	6 (13.9)	1 (0.83)	0.001

Data are n (%). CR: Complete remission; ESKD: End-stage kidney disease; KRT: Kidney replacement therapy; PR: Partial remission.